FDA approves IMAAVY® (nipocalimab-aahu) as first-ever treatment for warm autoimmune hemolytic anemia (wAIHA), representing a landmark advancement for patients

  • Post author:
  • Post category:Sales & Growth

IMAAVY is an immunoselective FcRn blocker designed to target and reduce pathogenic immunoglobulin G (IgG) autoantibodies while also preserving B-cell functionWarm autoimmune hemolytic anemia is a rare, life-threatening disease in which autoantibodies cause the destruction of red blood…

Continue ReadingFDA approves IMAAVY® (nipocalimab-aahu) as first-ever treatment for warm autoimmune hemolytic anemia (wAIHA), representing a landmark advancement for patients

Las Vegas Raiders Announce $25 Million Game-Changing Gift to Intermountain Health to Help Build Nevada’s First Stand-Alone Children’s Hospital

  • Post author:
  • Post category:Sales & Growth

Led by Raiders owners Mark Davis, Egon Durban, and Michael Meldman, this marks the largest philanthropic commitment in franchise historyLAS VEGAS, Aug. 24, 2026 /PRNewswire/ -- The Las Vegas Raiders and Intermountain Health today announced a $25 million gift to…

Continue ReadingLas Vegas Raiders Announce $25 Million Game-Changing Gift to Intermountain Health to Help Build Nevada’s First Stand-Alone Children’s Hospital

Liver Cirrhosis Market to Expand Significantly Through 2036, Driven by Emerging Therapies and Increasing Disease Burden | DelveInsight

  • Post author:
  • Post category:Sales & Growth

The liver cirrhosis market is expected to witness steady growth over the coming years, driven by the rising prevalence of chronic liver diseases, including hepatitis B, hepatitis C, alcohol-associated liver disease, and MASLD. In addition, a robust pipeline…

Continue ReadingLiver Cirrhosis Market to Expand Significantly Through 2036, Driven by Emerging Therapies and Increasing Disease Burden | DelveInsight

GC Biopharma’s Hunter Syndrome Treatment ‘Hunterase’ Receives Drug Approval in India and Taiwan

  • Post author:
  • Post category:Sales & Growth

- Secures approval for 'Hunterase IV' in India and both 'Hunterase IV & ICV' in Taiwan, accelerating expansion into the Asian rare disease market YONGIN, South Korea, Aug. 24, 2026 /PRNewswire/ -- GC Biopharma (006280.KS), a leading global…

Continue ReadingGC Biopharma’s Hunter Syndrome Treatment ‘Hunterase’ Receives Drug Approval in India and Taiwan

Rznomics Joins Lilly Gateway Labs in San Diego to Accelerate RNA Therapeutics

  • Post author:
  • Post category:Sales & Growth

SEONGNAM, South Korea, Aug. 23, 2026 /PRNewswire/ -- Rznomics Inc.(KOSDAQ: 476830), a biopharmaceutical company specializing in the development of RNA-based gene therapies, announced that it is joining Lilly Gateway Labs (LGL) in San Diego, California. Lilly Gateway Labs is…

Continue ReadingRznomics Joins Lilly Gateway Labs in San Diego to Accelerate RNA Therapeutics

Anbogen Therapeutics and The University of Tokyo Enter Collaborative Research Agreement to Evaluate ABT-301 Across Multiple Tumor Types, Targeting Accelerated Human Clinical Indication Expansion

  • Post author:
  • Post category:Sales & Growth

TAIPEI, Aug. 23, 2026 /PRNewswire/ -- Anbogen Therapeutics Inc. (TPEx: 7784) ("Anbogen" or the "Company"), a clinical-stage precision oncology company, today announced that it has entered into a Collaborative Research Agreement (CRA) with the Laboratory of Veterinary Surgery, Graduate…

Continue ReadingAnbogen Therapeutics and The University of Tokyo Enter Collaborative Research Agreement to Evaluate ABT-301 Across Multiple Tumor Types, Targeting Accelerated Human Clinical Indication Expansion

NEREUS™ Sponsored No. 47 IndyCar Ready for Historic Freedom 250 Grand Prix in Washington, D.C.

  • Post author:
  • Post category:Sales & Growth

WASHINGTON, Aug. 22, 2026 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Nasdaq: VNDA) today announced that the NEREUS™ branded No. 47 entry from Rahal Letterman Lanigan Racing, driven by Mick Schumacher, is set to compete this weekend in the inaugural…

Continue ReadingNEREUS™ Sponsored No. 47 IndyCar Ready for Historic Freedom 250 Grand Prix in Washington, D.C.

Understanding Lymph System Support Supplements: PureHealth Research Highlights Natural Ingredients for Everyday Wellness

  • Post author:
  • Post category:Sales & Growth

MANASSAS, Va., Aug. 22, 2026 /PRNewswire/ -- PureHealth Research is highlighting the growing consumer interest in lymphatic wellness through everyday nutrition. Lymph system support supplements are formulas that commonly feature botanicals such as Burdock Root, Cleavers, and Echinacea, ingredients…

Continue ReadingUnderstanding Lymph System Support Supplements: PureHealth Research Highlights Natural Ingredients for Everyday Wellness

Acadia Healthcare Investigation Continued: Kahn Swick & Foti, LLC Continues to Investigate the Officers and Directors of Acadia Healthcare Company, Inc. – ACHC

  • Post author:
  • Post category:Sales & Growth

NEW ORLEANS, Aug. 21, 2026 /PRNewswire/ -- Former Attorney General of Louisiana, Charles C. Foti, Jr., Esq., a partner at the law firm of Kahn Swick & Foti, LLC ("KSF"), announces that KSF continues its investigation into Acadia…

Continue ReadingAcadia Healthcare Investigation Continued: Kahn Swick & Foti, LLC Continues to Investigate the Officers and Directors of Acadia Healthcare Company, Inc. – ACHC

Armor Health Deploys ACE Geriatric Model of Care at Franklin County Ohio Correctional Facilities — Believed to Be a First in Correctional Healthcare

  • Post author:
  • Post category:Sales & Growth

MIAMI, Aug. 21, 2026 /PRNewswire/ -- Armor Health (ArmorHealthcare.com), a leading national provider of comprehensive correctional healthcare, today announced the deployment of the Acute Care for Elders (ACE) model of care at the Franklin County Correctional Facilities, with plans…

Continue ReadingArmor Health Deploys ACE Geriatric Model of Care at Franklin County Ohio Correctional Facilities — Believed to Be a First in Correctional Healthcare